Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

---

Szarek M., White H. D., Schwartz G. G., Alings M., Bhatt D. L., Bittner V. A., ...Daha Fazla

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, cilt.73, sa.4, ss.387-396, 2019 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 73 Sayı: 4
• Basım Tarihi: 2019
• Doi Numarası: 10.1016/j.jacc.2018.10.039
• Dergi Adı: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.387-396
• İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths.